Download PDF
CC BY-NC-ND 4.0 · Eur J Dent 2021; 15(02): 222-227
DOI: 10.1055/s-0040-1718637
Original Article

The Hormetic Effect of Arsenic Trioxide on Rat Pulpal Cells: An In Vitro Preliminary Study

Mohannad Nassar
1   Department of Preventive and Restorative Dentistry, College of Dental Medicine, University of Sharjah, Sharjah, United Arab Emirates
,
Ahmad Dargham
2   Ras Al Khaimah College of Dental Sciences, Ras Al Khaimah Medical and Health Sciences University, Ras Al Khaimah, United Arab Emirates
,
Ahmed Jamleh
3   Restorative and Prosthetic Dental Sciences, College of Dentistry, King Saud bin Abdulaziz University for Health Sciences, National Guard Health Affairs, Riyadh, Saudi Arabia
4   King Abdullah International Medical Research Centre, National Guard Health Affairs, Riyadh, Saudi Arabia
,
Yukihiko Tamura
5   Department of Bio-Matrix (Dental Pharmacology), Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
,
Noriko Hiraishi
6   Department of Cariology and Operative Dentistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
,
Junji Tagami
6   Department of Cariology and Operative Dentistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Objectives Despite the agreement that there is no longer any indication for arsenic use in modern endodontics, some concerns are surfacing about the minute amount of arsenic trioxide (As2O3) released from Portland cement-based materials. The present study investigated the effect of different concentrations of As2O3 on rat pulpal cells and the efficacy of N-acetylcysteine (NAC) in preventing As2O3-mediated toxicity.

Materials and Methods Cytotoxicities of 50, 10, or 5 µm As2O3 and the effect of cells co-treatment with 50 µm As2O3 and 5,000 µm NAC or 500 µm NAC were tested at 24 hours or 3 days. Cell viability was assessed by means of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay and cellular morphological changes were observed under phase contrast microscope.

Statistical Analysis Two-way analysis of variance with Tukey’s post-hoc test was used to evaluate differences between the groups (α = 0.05).

Results At both exposure times, 50 µm As2O3 resulted in lower optical density (OD) values when compared with 10 or 5 µm As2O3. At 24 hours, 10 µm As2O3 resulted in a higher OD value compared with the control; however, at 3 days the difference was statistically insignificant. At each exposure time, the OD value of 5 µm As2O3 group was comparable to the control and 10 µm As2O3 group. There were no significant differences between 50 µm As2O3 group and 500 μm NAC+50 μm As2O3 group; however, these two groups had lower OD values when compared with 5,000 μm NAC+50 μm As2O3 group at 24 hours and 3 days. The latter group showed significantly lower OD value in comparison with the control at 24 hours and 3 days. Control cells were polygonal-shaped while 50 µm As2O3-treated cells exhibited contracted and spherical morphology with increased intercellular spaces. At 24 hours, 10 μm and 5 µm As2O3-treated cells were slightly hypertrophic. Cells co-treated with NAC and As2O3 showed increased intercellular spaces and lower cellular density compared with the control.

Conclusions As2O3 displayed a hormetic effect on pulpal cells; however, the proliferative effect induced by low As2O3 concentrations should be interpreted with caution. NAC did not prevent As2O3-mediated toxicity; however, it demonstrated potential for ameliorating this toxicity.

Keywords

arsenic - heavy metal - hormesis - N-acetylcysteine - pulp cells - toxicity


Publication History

Article published online:
30 October 2020

© 2020. European Journal of Dentistry. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Agency for Toxic Substances and Disease Registry (ATSDR).. Toxicological Profile for Arsenic. Toxicological Profile for Arsenic U.S. Department of Health and Human Services. Public Health Service; 2007
    CrossrefGoogle Scholar
  • 2 Ratnaike RN. Acute and chronic arsenic toxicity. Postgrad Med J 2003; 79 (933) 391-396
    CrossrefPubMedGoogle Scholar
  • 3 Schmidt CW. Low-dose arsenic: in search of a risk threshold. Environ Health Perspect 2014; 122 (05) A130-A134
    CrossrefPubMedGoogle Scholar
  • 4 Hyson Jr JM. A history of arsenic in dentistry. J Calif Dent Assoc 2007; 35 (02) 135-139
    CrossrefPubMedGoogle Scholar
  • 5 Chen G, Sung PT. Gingival and localized alveolar bone necrosis related to the use of arsenic trioxide paste—two case reports. J Formos Med Assoc 2014; 113 (03) 187-190
    CrossrefPubMedGoogle Scholar
  • 6 Ali MS, Kano B. Endodontic materials: from old materials to recent advances. In: Khurshid Z, Najeeb S, Zafar MS, Sefat F. eds. Advanced Dental Biomaterials. Woodhead Publishing; Cambridge, UK:; 2019: 255-299
    CrossrefGoogle Scholar
  • 7 Oliveira MG, Xavier CB, Demarco FF, Pinheiro ALB, Costa AT, Pozza DH. Comparative chemical study of MTA and Portland cements. Braz Dent J 2007; 18 (01) 3-7
    CrossrefPubMedGoogle Scholar
  • 8 Guven Y, Tuna EB, Dincol ME, Aktoren O. X-ray diffraction analysis of MTA-Plus, MTA-Angelus and DiaRoot BioAggregate. Eur J Dent 2014; 8 (02) 211-215
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Phair JW. Green chemistry for sustainable cement production and use. Green Chem 2006; 8 (09) 763-780
    CrossrefGoogle Scholar
  • 10 Nejatian T, Firouzmanesh P, Syed AU. Dental gypsum and investments. In: Khurshid Z, Najeeb S, Zafar MS, Sefat F. eds. Advanced Dental Biomaterials. Woodhead Publishing; 2019. Cambridge, UK: 37-54
    CrossrefGoogle Scholar
  • 11 Islam I, Chng HK, Yap AU. Comparison of the physical and mechanical properties of MTA and Portland cement. J Endod 2006; 32 (03) 193-197
    CrossrefPubMedGoogle Scholar
  • 12 Schembri M, Peplow G, Camilleri J. Analyses of heavy metals in mineral trioxide aggregate and Portland cement. J Endod 2010; 36 (07) 1210-1215
    CrossrefPubMedGoogle Scholar
  • 13 Minotti PG, Ordinola-Zapata R, Midena RZ. et al. Rat subcutaneous tissue response to calcium silicate containing different arsenic concentrations. J Appl Oral Sci 2015; 23 (01) 42-48
    CrossrefPubMedGoogle Scholar
  • 14 Monteiro Bramante C, Demarchi ACCO, de Moraes IG. et al. Presence of arsenic in different types of MTA and white and gray Portland cement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106 (06) 909-913
    CrossrefPubMedGoogle Scholar
  • 15 Chang SW, Shon WJ, Lee W, Kum KY, Baek SH, Bae KS. Analysis of heavy metal contents in gray and white MTA and 2 kinds of Portland cement: a preliminary study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109 (04) 642-646
    CrossrefPubMedGoogle Scholar
  • 16 Dorileo MCGO, Bandeca MC, Pedro FLM. et al. Analysis of metal contents in Portland type V and MTA-based cements. ScientificWorldJournal 2014; 2014: 983728
    PubMedGoogle Scholar
  • 17 International Organization for Standardization. Dentistry—Water-based cements—Part 1: Powder/liquid acid-base cements. Geneva, Switzerland; 2007. ISO 9917-1:2003.
  • 18 De-Deus G, de Souza MCB, Sergio Fidel RA, Fidel SR, de Campos RC, Luna AS. Negligible expression of arsenic in some commercially available brands of Portland cement and mineral trioxide aggregate. J Endod 2009; 35 (06) 887-890
    CrossrefPubMedGoogle Scholar
  • 19 Duarte MAH, De Oliveira Demarchi ACC, Yamashita JC, Kuga MC, De Campos Fraga S. Arsenic release provided by MTA and Portland cement. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 99 (05) 648-650
    CrossrefPubMedGoogle Scholar
  • 20 Sochman J. N-acetylcysteine in acute cardiology: 10 years later: what do we know and what would we like to know?!. J Am Coll Cardiol 2002; 39 (09) 1422-1428
    CrossrefPubMedGoogle Scholar
  • 21 Modi M, Kaul RK, Kannan GM, Flora SJ. Co-administration of zinc and n-acetylcysteine prevents arsenic-induced tissue oxidative stress in male rats. J Trace Elem Med Biol 2006; 20 (03) 197-204
    CrossrefPubMedGoogle Scholar
  • 22 Reddy PS, Rani GP, Sainath SB, Meena R, Supriya Ch. Protective effects of N-acetylcysteine against arsenic-induced oxidative stress and reprotoxicity in male mice. J Trace Elem Med Biol 2011; 25 (04) 247-253
    CrossrefPubMedGoogle Scholar
  • 23 Kasugai S, Adachi M, Ogura H. Establishment and characterization of a clonal cell line (RPC-C2A) from dental pulp of the rat incisor. Arch Oral Biol 1988; 33 (12) 887-891
    CrossrefPubMedGoogle Scholar
  • 24 Hashmi MZ, Naveedullah. Shen H, Zhu S, Yu C, Shen C. Growth, bioluminescence and shoal behavior hormetic responses to inorganic and/or organic chemicals: a review. Environ Int 2014; 64: 28-39
    CrossrefPubMedGoogle Scholar
  • 25 Kitchin KT. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol 2001; 172 (03) 249-261
    CrossrefPubMedGoogle Scholar
  • 26 Rossman TG. Mechanism of arsenic carcinogenesis: an integrated approach. Mutat Res 2003; 533 (1-2) 37-65
    CrossrefPubMedGoogle Scholar
  • 27 Pilger A, Rüdiger HW. 8-Hydroxy-2′-deoxyguanosine as a marker of oxidative DNA damage related to occupational and environmental exposures. Int Arch Occup Environ Health 2006; 80 (01) 1-15
    CrossrefPubMedGoogle Scholar
  • 28 Valavanidis A, Vlachogianni T, Fiotakis C. 8-hydroxy-2′-deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health Part C Environ Carcinog Ecotoxicol Rev 2009; 27 (02) 120-139
    CrossrefPubMedGoogle Scholar
  • 29 Schmeisser S, Schmeisser K, Weimer S. et al. Mitochondrial hormesis links low-dose arsenite exposure to lifespan extension. Aging Cell 2013; 12 (03) 508-517
    CrossrefPubMedGoogle Scholar
  • 30 Lau ATY, Li M, Xie R, He QY, Chiu JF. Opposed arsenite-induced signaling pathways promote cell proliferation or apoptosis in cultured lung cells. Carcinogenesis 2004; 25 (01) 21-28
    PubMedGoogle Scholar
  • 31 Liao WT, Lan CC, Lee CH, Yu HS. Concentration-dependent cellular responses of arsenic in keratinocytes. Kaohsiung J Med Sci 2011; 27 (09) 390-395
    CrossrefPubMedGoogle Scholar
  • 32 Dodson M, de la Vega MR, Harder B. et al. Low-level arsenic causes proteotoxic stress and not oxidative stress. Toxicol Appl Pharmacol 2018; 341: 106-113
    CrossrefPubMedGoogle Scholar
  • 33 Snow ET, Sykora P, Durham TR, Klein CB. Arsenic, mode of action at biologically plausible low doses: what are the implications for low dose cancer risk?. Toxicol Appl Pharmacol 2005; 207 (suppl 2) 557-564
    CrossrefPubMedGoogle Scholar
  • 34 Udensi UK, Graham-Evans BE, Rogers C, Isokpehi RD. Cytotoxicity patterns of arsenic trioxide exposure on HaCaT keratinocytes. Clin Cosmet Investig Dermatol 2011; 4: 183-190
    PubMedGoogle Scholar
  • 35 Tokar EJ, Diwan BA, Waalkes MP. Arsenic exposure transforms human epithelial stem/progenitor cells into a cancer stem-like phenotype. Environ Health Perspect 2010; 118 (01) 108-115
    CrossrefPubMedGoogle Scholar
  • 36 Neuhaus KW. Teeth: malignant neoplasms in the dental pulp?. Lancet Oncol 2007; 8 (01) 75-78
    CrossrefPubMedGoogle Scholar
  • 37 Samanta J, Mondal A, Saha S, Chakraborty S, Sengupta A. Oleic acid protects from arsenic-induced cardiac hypertrophy via AMPK/FoxO/NFATc3 pathway. Cardiovasc Toxicol 2020; 20 (03) 261-280
    CrossrefPubMedGoogle Scholar
  • 38 Dash M, Maity M, Dey A. et al. The consequence of NAC on sodium arsenite-induced uterine oxidative stress. Toxicol Rep 2018; 5: 278-287
    CrossrefPubMedGoogle Scholar
  • 39 Kannan GM, Flora SJ. Combined administration of N-acetylcysteine and monoisoamyl DMSA on tissue oxidative stress during arsenic chelation therapy. Biol Trace Elem Res 2006; 110 (01) 43-59
    CrossrefPubMedGoogle Scholar
  • 40 Takahashi N, Yoshida T, Ohnuma A. et al. The enhancing effect of the antioxidant N-acetylcysteine on urinary bladder injury induced by dimethylarsinic acid. Toxicol Pathol 2011; 39 (07) 1107-1114
    CrossrefPubMedGoogle Scholar